Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCampistol, Miriam
dc.contributor.authorMorote Robles, Joan
dc.contributor.authorTriquell Llauradó, Marina
dc.contributor.authorRegis Plácido, Lucas
dc.contributor.authorCelma Domènech, Ana
dc.contributor.authorTorres Ramirez, Inés de
dc.contributor.authorSemidey Raven, Maria Eugenia
dc.contributor.authorMast, Richard
dc.contributor.authorSantamaria Margalef, Anna
dc.contributor.authorPlanas Morin, Jacques
dc.contributor.authorTrilla Herrera, Enric
dc.date.accessioned2022-09-09T13:22:12Z
dc.date.available2022-09-09T13:22:12Z
dc.date.issued2022-06
dc.identifier.citationCampistol M, Morote J, Triquell M, Regis L, Celma A, de Torres I, et al. Comparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI. Cancers. 2022 Jun;14(11):2702.
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/11351/8123
dc.descriptionProclarix; Clinically significant prostate cancer; Magnetic resonance imaging
dc.description.abstractTools to properly select candidates for prostate biopsy after magnetic resonance imaging (MRI) have usually been analyzed in overall populations with suspected prostate cancer (PCa). However, the performance of these tools can change regarding the Prostate Imaging-Reporting and Data System (PI-RADS) categories due to the different incidence of clinically significant PCa (csPCa). The objective of the study was to analyze PSA density (PSAD), MRI-ERSPC risk calculator (RC), and Proclarix to properly select candidates for prostate biopsy regarding PI-RADS categories. We performed a head-to-head analysis of 567 men with suspected PCa, PSA > 3 ng/mL and/or abnormal rectal examination, in whom two to four core transrectal ultrasound (TRUS) guided biopsies to PI-RADS ≥ three lesions and/or 12-core TRUS systematic biopsies were performed after 3-tesla mpMRI between January 2018 and March 2020 in one academic institution. The overall detection of csPCa was 40.9% (6% in PI-RADS < 3, 14.8% in PI-RADS 3, 55.3% in PI-RADS 4, and 88.9% in PI-RADS 5). MRI-ERSPC model exhibited a net benefit over PSAD and Proclarix in the overall population. Proclarix outperformed PSAD and MRI-ERSPC RC in PI-RADS ≤ 3. PSAD outperformed MRI-ESRPC RC and Proclarix in PI-RADS > 3, although none of them exhibited 100% sensitivity for csPCa in this setting. Therefore, tools to properly select candidates for prostate biopsy after MRI must be analyzed regarding the PI-RADS categories. While MRI-ERSPC RC outperformed PSAD and Proclarix in the overall population, Proclarix outperformed in PI-RADS ≤ 3, and no tool guaranteed 100% detection of csPCa in PI-RADS 4 and 5.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;14(11)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectPròstata - Càncer - Diagnòstic
dc.subjectPròstata - Biòpsia
dc.subject.meshBiopsy
dc.subject.meshProstate-Specific Antigen
dc.subject.meshProstatic Neoplasms
dc.subject.mesh/diagnosis
dc.titleComparison of Proclarix, PSA Density and MRI-ERSPC Risk Calculator to Select Patients for Prostate Biopsy after mpMRI
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers14112702
dc.subject.decsbiopsia
dc.subject.decsantígeno prostático específico
dc.subject.decsneoplasias de la próstata
dc.subject.decs/diagnóstico
dc.relation.publishversionhttps://doi.org/10.3390/cancers14112702
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Campistol M, Triquell M] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Morote J, Trilla E] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Càncer de Pròstata, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Regis L, Celma A, Planas J] Servei d’Urologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Càncer de Pròstata, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [de Torres I, Semidey ME] Grup de Recerca en Càncer de Pròstata, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Ciències Morfològiques, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Mast R] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Santamaría A] Grup de Recerca en Càncer de Pròstata, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid35681685
dc.identifier.wos000808877100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record